Shop for $75 or more and get 13% off
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      CDI, Promega Partner To Develop In-Vitro Assays For Drug Discovery

      Posted AtPharmaceutical-business-review.com

      Cellular Dynamics International (CDI) and Promega have entered into a research collaboration to bring predictive in-vitro toxicity testing to the drug discovery process.

      Currently CDI has validated a panel of cell-based cytotoxicity assays from Promega that use CDI’s human induced pluripotent stem (iPS) cell-derived iCell Cardiomyocytes. CDI and its pharmaceutical collaborators have begun validating such assays in order to incorporate them into their routine discovery programs.

      CDI has presented data at the recent Society of Toxicology and the Society of Biomolecular Science conferences demonstrating that Promega’s multiplexed biomarker assays for cytotoxicity and cell viability can be used to identify known toxic agents with similar sensitivity as reported in the published literature.

      Pharmaceutical discovery scientists will be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

      Chris Parker, chief commercial officer of CDI, said: “Pharmaceutical customers recognize the importance of using human models to perform their studies but up until recently, human cell models that exhibited true human biology in vitro were difficult to come by.

      "We have several pharmaceutical customers who’ve validated in vitro cardiotoxicity assays using iCell Cardiomyocytes, which have correlated well with previous data from cardiotoxicity studies in animal-based models."

      Headquartered in Madison, USA, Promega is a provider of solutions and technical support to the life sciences industry. The company’s products enable scientists to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.

      June 23, 2010


       

      Share this Article!

    Back to top^